<DOC>
	<DOCNO>NCT00002630</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining peripheral stem cell transplantation chemotherapy radiation therapy may allow doctor give high dos radiation chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness high-dose melphalan plus total-body irradiation peripheral stem cell transplantation treat patient multiple myeloma first relapse .</brief_summary>
	<brief_title>High-Dose Melphalan , Total-Body Irradiation , Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma First Relapse</brief_title>
	<detailed_description>OBJECTIVES : I. Assess bone marrow reconstitution peripheral blood cell count patient multiple myeloma treat high-dose melphalan ( L-PAM ) total-body irradiation ( TBI ) follow peripheral blood stem cell ( PBSC ) rescue . II . Assess efficacy intravenous L-PAM TBI treatment relapsing/refractory myeloma . III . Assess tolerability toxicity regimen patient relapse multiple myeloma . IV . Assess response rate survival relapsing/refractory patient treat regimen . OUTLINE : Prior entry , patient receive 3 monthly course standard VAD follow PBSC collection Regimen A ; respond VAD continue standard VAD best response upon relapse ( therapy ) proceed Regimen B . Patients response 3 course VAD response alkylating-based regimen proceed immediately Regimen B follow PBSC collection . The following acronym use : CTX Cyclophosphamide , NSC-26271 G-CSF Granulocyte Colony Stimulating Factor ( Amgen ) , NSC-614629 L-PAM Melphalan , NSC-8806 PBSC Peripheral Blood Stem Cells VAD Vincristine/Doxorubicin/Dexamethasone TBI Total Body Irradiation Regimen A : Stem Cell Mobilization/Harvest . CTX ; G-CSF . Regimen B : Single-Agent Myeloablative Chemoradiotherapy Stem Cell Rescue . L-PAM ; TBI ( Co60 linear accelerator 4 MV great ) ; PBSC . PROJECTED ACCRUAL : If 9 few 20 response see first 50 patient treat , study discontinue .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Multiple myeloma confirm bone marrow plasmacytosis measurable Mcomponent serum urine immunoelectrophoresis immunofixation No Stage I myeloma No smolder multiple myeloma Refractory first relapse follow initial response VAD ( vincristine/doxorubicin/dexamethasone ) , relapse define follow : 50 % increase low remission level serum urine Mprotein therapy 2550 % increase low remission level serum urine Mprotein associate either : Hypercalcemia ( great 11 mg/dl ) Hb decrease 2 g/dl attributable increase marrow plasmacytosis Appearance new lytic lesion Calcium great 11 mg/dl No myeloma meningitis No plasma cell leukemia PATIENT CHARACTERISTICS : Age : 18 65 Performance status : ECOG 02 Hematopoietic : WBC great 500 ( GCSF ) Platelets great 25,000 Hepatic : Bilirubin great 2.0 mg/dl Renal : Creatinine great 2.0 mg/dl Cardiovascular : No NYHA class IIIV disease Pulmonary : DLCO least 50 % predict FVC least 75 % predict FEV1 least 60 % predict Other : No uncontrolled infection No active fungal infection No fever No prior malignancy within 5 year except : Basal cell skin cancer In situ carcinoma cervix No pregnant nursing woman PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biological response modifier allow Chemotherapy : No time limit cytotoxic therapy protocol treatment Prior cumulative melphalan dose less 300 mg Endocrine therapy : Corticosteroids hypercalcemia allow Radiotherapy : Prior radiotherapy allow Prior pelvic radiotherapy allow , patient therapy unlikely adequate PBSC harvest Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>